Canada Markets closed

Covalon Technologies Ltd. (COV.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
2.20000.0000 (0.00%)
At close: 03:25PM EST

Covalon Technologies Ltd.

1660 Tech Avenue
Unit 5
Mississauga, ON L4W 5S7

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Brian E. PedlarPres, CEO & Director897.5kN/AN/A
Simon SmithChief Exec. Officer of Covalon Technologies (Europe) Ltd.290.64kN/AN/A
Gerry ArambulaPres of Covalon Technologies AG Ltd.634.76kN/AN/A
Dr. Valerio DiTizioCo-Founder, Chief Scientific Officer & VPN/AN/A1968
Mr. Jason F. GorelInterim Chief Financial OfficerN/AN/AN/A
Ms. Elaine ZhangVP of OperationsN/AN/AN/A
Mr. Ron HebertSr. VP of MarketingN/AN/AN/A
Mr. Greg LeszczynskiVP of HRN/AN/AN/A
Mr. Mark DoolittleSr. VP of Commercial SalesN/AN/AN/A
Mr. Hamed AbbasianVP of Bus. Devel.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has 3 proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform that is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. Its products include wound care dressings; surgical and peri-operative products; and infection management products. The company offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. It serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. The company is headquartered in Mississauga, Canada.

Corporate Governance

Covalon Technologies Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.